HLA Typing Transplant Diagnostic Services Market Future Opportunities 2026

HLA typing recognizes the exceptional group of HLA antigens for a person. Identification of HLA-class I and class II antigens is carried out by molecular diagnostic procedures based on DNA. HLA typing utilizing these advanced DNA innovations and provides more vigorous, accurate testing results that are reliable in identifying difference in HLA genes.

Report Overview @ https://www.transparencymarketresearch.com/hla-typing-transplant-diagnostic-services-market.html

Technological developments in HLA typing, increase in number of procedures involving solid organ, stem cell transplantation, and soft tissue transplantation, rise in support in research and development, surge in investment in public private funds are the major factors driving the global HLA typing transplant diagnostics services market. However, unfavorable reimbursement policies for organ transplantation and donation procedures and high cost of polymerase chain reaction-based technological devices hamper the growth of the market. Moreover, shift in technology from serological assays to HLA profiling which is gene based and advancements in health care facilities across emerging countries present significant opportunities for HLA typing transplant players in the market. Significant gap between the number of organ donors and the number of organs that are required annually restrains the global HLA typing transplant diagnostic services market.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=43394

Based on technology, the global HLA typing transplant diagnostics services market can be segmented into molecular assay technology [polymerase chain reaction (PCR)], and sequencing based [next-generation sequencing (NGS)] and non-molecular assay technology. The polymerase chain reaction (PCR) segment is projected to dominate the global HLA typing transplant diagnostics services market. However, the next-generation sequencing segment is anticipated to grow at a rapid pace during the forecast period. The polymerase chain reaction segment can be sub-segmented into PCR-SSP (sequence-specific primer), PCR SSOP (sequence-specific oligonucleotide), and PCR-SBT (sequencing based typing). The PCR-SSP sub-segment is expected to dominate the polymerase chain reaction segment. However, the PCR-SBT segment is likely to expand at a high CAGR during the forecast period. In terms of end-user, the global HLA typing transplant diagnostics services market can be classified into hospitals, transplant centers, specialty clinics, and academic institutes. The hospitals segment is expected to dominate the global HLA typing transplant diagnostics services market during the forecast period.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=43394

Geographically, the global HLA typing transplant diagnostics services market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Industrially developed nations in Europe and North America such as the U.S. and Canada account for the largest share of the global market owing to rise in prevalence of chronic diseases such as cancer, cardiac, and renal associated diseases. However, increase in access and high adoption of advanced diagnostic technologies, advancements in technologies related to HLA-based transplant diagnostics, and high growth have been witnessed in emerging markets in Asia Pacific. Demand for HLA typing transplant diagnostics services in Asia Pacific is driven by high population growth, increase in awareness, and rise in investments in health care infrastructure. Major players in the market are focusing on this region to compensate for the sluggish business in highly competitive markets in the West. Leading players in the diagnostic services market are acquiring smaller technology companies to produce companion diagnostic services and expand them.

Key players operating in the HLA typing transplant diagnostics services market are One Lambda (Thermo Fischer Scientific, Inc.), Proimmune Ltd., Immucor, Inc., Creative Biolabs, Olerup SSP AB, Histogenetics LLC, QIAGEN, Inc., The UCLA Immunogenetics Center, Affymetrix, Inc., Admera Health, Illumina, Inc., Quick Biology, New York Blood Center, The Sequencing Center, F. Hoffmann-La Roche Ltd., BloodCenter of Wisconsin, and Laboratory Corporation of America Holdings.

Fertility Services Market Growth, Capacity, Scope, Revenue, Key-Players, and Forecast until 2025

Fertility services are services provided to support the treatment to cure infertility. Fertility services involve techniques such as in vitro fertilization (IVF), artificial insemination, and surrogacy, which help in resolving infertility issues among couples, single mothers, and the LGBT community. Infertility can occur in men or women of child-bearing age. Male infertility is identified majorly as a result of low sperm count or decreased motility of sperms, which may be due to hormonal imbalance. Hence, fertility in men and women requires proper functioning of hypothalamus and pituitary gland. Increase in the rate of infertility has occurred majorly due to factors such as increase in the consumption of alcohol and drugs, increased stress level, frequent smoking, obesity, and environmental factors. As per a study by the American Society for Reproductive medicines, in approximately 40% of infertile couples, the male partner is responsible for infertility and among them, approximately 85%–90% are treated with drugs or surgery.

Report Overview @ https://www.transparencymarketresearch.com/fertility-services-market.html

The global fertility services market can be segmented based on cause of infertility, type of treatment, and service provider. Based on cause of infertility, the Fertility services market can be segmented into male infertility and female infertility. In terms of type of treatment/technology involved, the global fertility services market can be divided into assisted reproductive technology (ART), in vitro fertilization (IVF), artificial insemination (AI) by donor type, artificial insemination by medical practitioner, and others. The in vitro fertilization segment has been sub-segmented into intracytoplasmic sperm injection (ICSI) and pre-implantation genetic diagnostics (PGD). The artificial insemination segment has been sub-segmented into intrauterine insemination, intracervical insemination, and others.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42119

High success rate and technological advancements in the new devices for IVF treatment are likely to propel the segment during the forecast period. Rise in the rate of infertility, low cost of artificial insemination and surrogacy in developing countries, rising incidence of reproductive tourism and cross-border reproductive care are estimated to drive artificial insemination and surrogacy segments during the forecast period. The others segment is anticipated to sustain Fertility services market share by the end of the forecast period, due to high cost and low awareness about GIFT and ZIFT technologies and dominance of IVF and surrogacy segments in the global Fertility services market. Based on service provider, the Fertility services market has been classified into fertility clinics, hospitals, and others. The fertility clinics segment is projected to hold the highest Fertility services market share between 2017 and 2025, due to constant rise in the number of fertility clinics, high success rate of fertility treatment in clinics due to adoption of advanced technology, tie-ups of clinics with consultants, and rising fertility tourism. On the other hand, the hospitals segment is expected to expand during the forecast period, due to advanced procedures and equipment, availability of expert doctors, and ongoing research in hospitals for improving the success rate of the ART treatment.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=42119

Geographically, the global fertility services market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. EMEA led the global fertility services market with countries such as the U.K., France, Germany, Italy, and Spain being major contributors to the revenue. Primary factors augmenting the Fertility services market in the region are increased demand for infertility treatments and increase in sedentary lifestyle.

Key players operating in the global fertility services market are CooperSurgical, Care Fertility, Apollo Hospitals Enterprise Ltd., Ferring Pharmaceuticals, Carolinas Fertility Institute, Merck, INVO Bioscience, Monash IVF, OvaScience Inc., Fertility Focus Ltd., and Vitrolife.

Dental Milling Machine Market: Overview with Detailed Analysis, Competitive landscape Forecast to 2026

Dental milling machine is utilized to design and make simulated dental prosthetics. The various types of dental milling machines are dry-milling dental machines and wet-milling dental machines. These make great extensions, crowns, and restorations. Computer aided design/ computer-aided manufacturing (CAD/CAM) is a branch of dentistry. Prosthodontics utilizes CAD/CAM to enhance the design and formation of dental restorations, particularly prostheses in dental field, including crowns, dental implants, inlays and onlays, crowns, and fixed bridges, etc.

Report Overview @ https://www.transparencymarketresearch.com/dental-milling-machine-market.html

Rise in occurrence of dental disorders, increase in geriatric population that is at high hazard for tooth deformations, surge in cases of trauma that leads to tooth deformations, and rise in technological innovation in dentistry are the factors driving the global dental milling machines market. However, unfavorable reimbursement policies for cosmetic dentistry is projected to hamper the growth of the dental milling machine market in the near future. Rise in dental tourism and development openings in growing economies in Asia Pacific and LAMEA are also likely to propel the market. Surge in preference for dental corrective surgeries is expected to augment the market in the next few years. Expenditure on cosmetic dentistry has increased in the past few years. Non-metallic trims or onlays held a substantial share of the segment. Teeth brightening is the most performed procedure. Tooth-colored crowns, tooth-shaded inlays, tooth-shaded onlays, and bonding are the major contributors to the surgical procedures. Advancement in medical facilities has led to an increase in the geriatric population. These factors are likely to drive demand for CAD/CAM milling machines in the near future.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42065

The global dental milling machine market can be segmented based on product type, product size, technology, and end-user. In terms of product type, the dental milling machine market can be bifurcated into in-lab milling machines and in-office milling machines. Based on product size, the global dental milling machine market can be classified into tabletop, bench-top, and standalone. In terms of technology, the dental milling machine market can be categorized into CAD/CAM milling and copying milling machines. Based on end-user, the global dental milling machine market can be divided into dental clinics, hospitals, dental companies, and others. The hospitals segment accounted for the largest dental milling machine market share in 2016. For surgical procedures, patients prefer dental hospitals to be safer due to easily accessible doctors.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=42065

The global dental milling machine market has a presence of large number of regional players who hold significant dental milling machine market share in emerging countries and operate at regional or country level. Geographically, the global dental milling machine market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the major market share due to significant contribution from the U.S. as it is the leading player in the global market. Factors such as rise in cases of dental caries, high patient awareness, and advanced health care facilities drive the market in the U.S. and Canada. Europe is the second largest market for dental milling machines. However, the dental milling machine market in Asia Pacific is expected to grow rapidly during the forecast period owing to rise in per capita income and increase in geriatric population in the region.

Major players in the global dental milling machine market include Amann Girrbach, Dentsply Sirona, CadBlu Dental, Ivoclar Vivadent, 3M Company, Straumann, Zimmer, Dentium, Imes-icore, DATRON, B&D Dental, Zubler, Zirkonzahn, Bien-Air Dental, Interdent, Mecanumeric, Willemin-Macodel, Danaher Corporation, Reitel Feinwerktechnik, Schutz Dental, and Georg Schick.

Malaria Treatment Market Growth Opportunities & Technology Developments by 2025

The impact of malaria is serious and getting worse throughout the world. Malaria remains a significant cause of death and illness amoMalaria Treatment Markeng adults and children. Controlling of malaria needs an incorporated approach, comprising prompt treatment and prevention with effective antimalarial agents. Malaria is typically prevalent in hot climate. Anopheles mosquito, that transfers malaria parasite from one person to another, thrives in warm, moist climate where ponds of water offer it the perfect breeding platforms. Malaria is highly prevalent in conditions where health care systems are inadequate and awareness is low. Malaria is curable disease if effective treatment is initiated early. Delay in action may lead to severe implications, including death. Effective and prompt treatment is also important for controlling the spread of malaria. The cost of malaria is enormous for human and social being as the disease typically attacks not once but repeatedly into affected victims. The World Bank and the World Health Organization (WHO) rank malaria as the single largest factor of disease in Africa, causing disability and premature mortality.

Report Overview @ https://www.transparencymarketresearch.com/malaria-treatment-market.html

Increase in government expenditure for prevention of malaria is a key driving factor for the malaria treatment market. According to the WHO, the estimated total funding for control and elimination of malaria was US$ 2.9 Bn in 2015. Moreover, in 2015, around 212 million cases of malaria were reported and 429,000 deaths were caused by malaria globally. Thus, high prevalence and disease burden of malaria are expected to drive the malaria treatment market during the forecast period.

The global malaria treatment market can be segmented depending on treatment type, route of administration, end-user, and geography. Based on treatment type, the global malaria treatment market can be categorized into vaccines, anti-malarial agents, diagnostic tests, and indicators. On the basis of route of administration, the malaria treatment market can be classified into oral, intravenous, and parenteral. Based on end-user, the global malaria treatment market can be divided into hospitals, specialty clinics, and others.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41990

In terms of geography, the global malaria treatment market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Further, the malaria treatment market in North America can be bifurcated into the U.S. and Canada. The malaria treatment market in Europe can be divided into the U.K., Germany, France, Italy, Spain, and Rest of Europe. The malaria treatment market in Asia Pacific can be further classified into Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific. Mexico, Brazil, and Rest of Latin America are the sub-segments of the malaria treatment market in Latin America, while the market in Middle East & Africa comprises Saudi Arabia, South Africa, Israel, and Rest of Middle East & Africa. Prevalence of malaria is higher in Asia Pacific and Middle East & Africa region as compared to that in North America and Europe. According to statistics published by the WHO in 2016, the highest number cases of malaria were detected in Asia Pacific and Middle East & Africa. It is estimated that 53% of the population in Middle East & Africa is at risk of malaria. According to the WHO, 58% of the cases of malaria caused by P. vivax occurs in Asia Pacific, followed by Middle East & Africa. Moreover, around 76% of the registered cases of malaria in 2015 were from just 13 countries. India, Ethiopia, Pakistan, and Indonesia accounted for high prevalence of malaria due to P. vivax.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=41990

Some of the key players operating in malaria treatment market are Novartis AG, Pfizer, Inc., Amyris, GlaxoSmithKline, Concordia International Corp., Lannett Company, Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals, Inc., Fresenius Kabi, LLC, Roxane Laboratories, Inc., Baxter International Inc., and Sanofi.

Narcotic Analgesic Combination Drugs Market: Research Analysis by Basic Information, Manufacturing Base, Sales Area and Regions

Narcotic analgesic combination drugs are medicines that contain an opiate pain reliever, with at least one different analgesic such as acetaminophen or ibuprofen. These should be utilized to treat direct to extreme pain when other less intense analgesics are not effective. Narcotic analgesics (also called sedatives, opioid analgesics, or opiates) ease intense and chronic extreme pain by binding to opioid receptors. The three types of opioid receptors are mu, delta, and kappa. Most opiate analgesics combination bind to the narcotic “mu” receptor and are extremely effective in relieving pain. However, these also initiate remunerate pathways implying that narcotic analgesic combination tends to cause dependence and addiction (where expanding doses are expected to give a similar pain-relieving effect). Diverse opiate pain relieving mixes have distinctive potencies and reactions in view of the ingredients these contain.

Report Overview @ https://www.transparencymarketresearch.com/narcotic-analgesic-combination-drugs-market.html

Rise in prevalence of osteoarthritis, back pain, and rheumatoid arthritis are the major factors propelling the global narcotic analgesic combination drugs market. Increase in incidence of overactive bladder also drives the narcotic analgesic combination drugs market. However, side effects of drugs such as constipation, vomiting, loss of appetite, and urination problem, and death due to overdose of narcotic analgesic combination drugs are factors likely to restrain the market in the next few years.

Based on indication, the global narcotic analgesic combination drugs market can be segmented into chronic cough, osteoarthritis, rheumatoid arthritis, and others. The osteoarthritis segment is likely to expand at a rapid pace during the forecast period. This can be attributed to rise in geriatric population with osteoarthritis. In terms of drug class, the global Narcotic Analgesic Combination Drugs market can be categorized into opiate agonists, analgesics, and others. The analgesics segment is likely to expand at a rapid pace during the forecast period, attributed to high preference by doctors to relieve pain, as it has low side effects and help prevent blood clots in elderly patients. Based on route of administration, the global narcotic analgesic combination drugs market can be classified into oral, intravenous, and intramuscular. The oral segment is likely to expand at a rapid pace during the forecast period. Oral administration is the most frequently preferred route by doctors because of its simplicity and convenience. Moreover, the degree of bioavailability of oral dose form of narcotic analgesic combination drugs is high and for this reason it quickly absorbed in the blood, only a tract amount remain in the gastrointestinal tract.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42071

In terms of region, the global narcotic analgesic combination drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Growth of the narcotic analgesic combination drugs market in North America is attributed to favorable reimbursement policies for prescription drugs. Rise in geriatric population with osteoarthritis pain and availability of wide range of over-the-counter drugs for pain management are likely to propel the narcotic analgesic combination drugs market in Europe. Increase in geriatric population and rising awareness among the health professionals to address different diseases and infection through various combination drugs are anticipated to drive the market in Asia Pacific. Rise in prevalence of neuropathic pain, arthritic pain, and chronic back pain in Africa is expected to propel the narcotic analgesic combination drugs market in Middle East & Africa during the forecast period.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=42071

Key players operating in the global narcotic analgesic combination drugs market are BioDelivery Sciences International, Inc., Pfizer Inc., Allergan plc, Teva Pharmaceuticals, Akron, Inc., UCB, Inc., and Endo Pharmaceuticals, Inc., among others.

Antidotes Market: Growth, Trends and Demands Research Report and Forecast 2025

Antidotes are medicines, chelating drugs, or pharmaceutical ingredients that neutralize the effect of poison or another drug. Paracetamol poisoning is the major concern all over the world as it is the most common drug taken in intentional overdose. Opioid poisoning, cyanide poisoning, benzodiazepine poisoning and other toxins can be neutralized using antidotes. Different types of antidotes are available to neutralize the effect of one particular drug and to reduce the toxicity of many drugs. There are antidotes that are 100% effective, while some can cause fatalities. Examples of antidotes are pralidoxime for poisoning by anti-cholinesterase nerve agents, naloxone for opioid overdose, methylene blue for drug-induced methemoglobinemia, flumazenil for benzodiazepine overdose, dimercaprol for arsenic, gold, or inorganic mercury poisoning, digoxin immune fab for digoxin toxicity, atropine for organophosphates and carbamates, activated charcoal for most poisons, and acetylcysteine for acetaminophen poisoning.

Report Overview @ https://www.transparencymarketresearch.com/antidotes-market.html

According to the World Health Organization (WHO), over 5 million people across the world suffer from snake bites each year, and nearly 100,000 of these develop severe sequela. Mortality rate in developing countries in Asia Pacific such as India was approximately 30,000, whereas in developed countries in North America such as the U.S. it was 50,000 cases of bites, of which 7,000 were by venomous snakes.

Increase in awareness and studies regarding the identification of toxins of venomous bites by companies and governments to increase the knowledge of antidotes and drugs is projected to drive the global antidotes market during the forecast period. Rise in prevalence of the medical conditions associated with antidotes such as trichotillomania, toxoplasmosis prophylaxis, smoking cessation, reversal of sedation, reversal of opioid sedation, pneumocystis pneumonia prophylaxis, and opioid overdose drives demand for antidotes. However, rise in prices of anti-venoms is anticipated to restrain the global antidotes market during the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42023

The global antidotes market can be segmented based on antidote type, dosage form, mode of action, and region. In terms of antidote type, the market can be categorized into chemical antidotes, physical antidotes, and pharmacological antidotes. Based on dosage form, the global antidotes market can be bifurcated into oral and injectable. Oral dosage can be divided into capsules or tablets, and syrup. Based on mode of action, the market can be segmented into poison, drug, and toxin.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=42023

Geographically, the global antidotes market can be segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held the largest market share in 2016, due to increase in research and development on antidotes in the region. Europe held the second largest market share in 2016, due to technological advancements in antidotes. The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period owing to increase in prevalence of medical conditions associated with antidotes such as nerve agent poisoning, methotrexate rescue, methanol poisoning, mercury poisoning, lead poisoning, and gold poisoning. The market in Latin America and Middle East & Africa is anticipated to be driven by rise in government initiatives regarding antidotes.

Key players in the global antidotes market include ADAPT Pharma, Inc., Baxter International, Inc., Cumberland Pharmaceuticals, Inc., Meridian Medical Technologies, Inc., Graceway Pharmaceuticals, LLC, Luitpold Pharmaceuticals, Inc., Novartis AG, Protherics, Inc., ApoPharma USA, Inc., Apotex, Inc., and Spectrum Pharmaceuticals, Inc.

Endoscopy Irrigation Pumps Market Growth, Capacity, Scope, Revenue, Key-Players, and Forecast until 2025

Endoscopy is a minimally invasive procedure performed to examine internal cavities or lumen in the body such as the gastrointestinal track, pericardial cavity, space around joints, etc.. Body fluids obstruct the visualization of tissue parts, which need to be irrigated with water or other cleaning solutions. Irrigation is also recommended to enhance the visualization in ultrasound endoscopy. Moreover, irrigation offers inflation of body cavity thereby easing the endoscopy procedure. Irrigation is achieved using dedicated irrigating pumps that have controlled operation to release a predefined quantity of water or cleansing solute. The irrigation pumps are attached to the endoscope or opening and irrigation port through polyfluorene or polyethylene tubing. Endoscopy irrigation systems are simple units comprising a reservoir, a peristaltic pump, controller unit, and connecting tubing. Some systems are offered with optional water or solute warming capacities to provide warm water for irrigation.

Report Overview @ https://www.transparencymarketresearch.com/endoscopy-irrigation-pumps-market.html

Irrigation pumps have been an integral part of many endoscopy procedures such as arthroscopy, laparoscopy, ureteroscopy, etc. However, other specialties such as gastroenterology and obstetrics & gynecology are also incorporating these devices in their routine endoscopy practices, which is likely to drive expansion of the endoscopic irrigation pumps market. Moreover, health care providers are adopting national and international accreditations, which is expected to lead health care providers to standardize their endoscopic practices using ancillary equipment such as irrigation pumps. Demand for better diagnosis, patient safety, and ease of operation are anticipated to increase use of endoscopic irrigation pumps in near future. However, low cost and quality of endoscopic irrigation pumps offered by numerous local suppliers are anticipated to hamper the global endoscopic irrigation pumps market during the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41981

The global endoscopic irrigation pumps market can be segmented based on application, end-user, and region. In terms of application, the endoscopic irrigation pumps market can be classified into gastroenterology, laparoscopy, arthroscopy, obstetrics & gynecology, and others. Adoption of gastroenterology endoscopy is increasing and so are the therapeutic endoscopy procedures. Irrigation pumps are used to clean the mucus wall of the intestinal tract for better visualization. Many of the key players in the endoscopy sector are offering irrigation pumps. These factors are likely to drive expansion of the global endoscopic irrigations pumps market. Irrigation is an integral part of arthroscopy procedures. This is estimated to fuel expansion of the arthroscopy segment during the forecast period. Based on end user, the global endoscopic irrigation pumps market can be segmented into hospitals, ambulatory surgical centers, and specialty clinics. Endoscopic procedures are minimally invasive and are performed on a day care basis. A rise in their adoption in ambulatory surgical centers is likely to propel demand for endoscopy irrigation pumps in ambulatory surgical centers.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=41981

In terms of region, the global endoscopic irrigation pumps market can be classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to hold a prominent share of the global endoscopic irrigation pumps market during the forecast period, due to high adoption of minimally invasive techniques such as endoscopy and demand for patient safety and operating standards. Europe is anticipated to account for a significant share of the global endoscopic irrigations pumps market during the forecast period. Asia Pacific is likely to account for a prominent share of the global endoscopic irrigations pumps market in the near future. The market in the region is expected to expand at a rapid pace due to an increase in expenditure on development of health care infrastructure in emerging countries such as China and India.

Major players operating in the global endoscopic irrigation pumps market are Olympus Corporation, MEDIVATORS Inc., B. Braun Medical Ltd, WISAP Medical Technology GmbH, Stryker, RUDOLF Medical GmbH + Co. KG., EMED, US Endoscopy, joimax GmbH, Fujifilm Holdings Corporation, and LEMKE.

Whole Exome Sequencing (WES) Market Size, Status and Forecast to 2026

Whole exome sequencing (WES) is a new technology used for systematically sequencing all the stated genes in an exome (also known as genome). The exome includes the total of all exons present in an organism. A human being has about 180,000 exons, creating around 1% of the human genome, or around 30 million base pairs and is converted into proteins after translation process. It is responsible for the incidence of nearly 85% of hereditary or genetic diseases. It is also called complete exome sequencing. This sequencing technique is commonly used to identify or detect the genetic factor responsible for various diseases such as Alzheimer’s and Miller syndrome.

Report Overview @ https://www.transparencymarketresearch.com/whole-exome-sequencing-market-.html

The global whole exome sequencing market is expected to grow at a rapid pace due to factors such as rapidly declining costs of sequencing, strategic alliances among major companies and research institutes, adoption of WES technology by new consumers, and increase in use of whole exome sequencing technology for new applications. Increase in acceptance of next generation sequencing methods for prediction, treatment, and monitoring of diverse chronic diseases such as cancer is likely to drive the market. However, lack of skilled professionals and legal issues associated with the technique restrain the global whole exome sequencing market. Furthermore, high demand for personalized medicine and development of new innovative products by key players provide numerous opportunities for market expansion in the near future.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42125

The global whole exome sequencing market can be segmented based on technology, products and services, applications, end-user, and region. In terms of technology, the market can be classified into ion semiconductor sequencing, sequencing by synthesis, and others. Based on products and services, the global whole exome sequencing market can be divided into kits (consumables), systems and platforms, and services. The kits segment can be sub-segmented into library preparation kits, target enrichment kits, and others. The services segment can be divided into sequencing services, data analysis services, and others. In terms of application, the market can be categorized into drug discovery and development, personalized medicine, diagnostics, animal and plant research, and others. Based on end-user, the global whole exome sequencing market can be segmented into academic and government institutions, research centers, pharmaceutical and biotech companies, and others.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=42125

Geographically, the global whole exome sequencing market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region can be divided into specific countries such as the U.S., Canada, the U.K., Germany, Brazil, China, India, and GCC Countries. North America dominated the global whole exome sequencing market because of the relatively large federal grants from the National Institutes of Health (NIH), increase in use of exome sequencing in uncommon sickness investigation, and improved government subsidy. Asia Pacific is projected to be the most attractive market during the forecast period due to rise in health awareness and demand for advanced medical technology.

Key players operating in the whole exome sequencing market are Macrogen, Inc., Ambry Genetics, Illumina, Inc., Knome, Inc., Life Technologies, Agilent Technologies, Roche NimbleGen, Inc., Sengenics, GENEWIZ, Inc., Eurofins Genomics, Inc., and BGI (Beijing Genomics Institute), among others. These players have adopted strategies such as collaborations, partnerships, agreements, and new product launches to gain competitive advantage in the market.

AIDS Associated Dementia Market Scope and Opportunities Analysis 2014 – 2020

Dementia is characterized by a set of symptoms which includes loss of mental abilities such as social abilities, thinking, memory and judgment. Dementia is severe enough to affect an individual’s daily activities and functions accompanied by certain changes in personality. A person with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) develop severity of dementia, termed as AIDS associated dementia or AIDS Dementia Complex (ADC). AIDS associated dementia is primarily caused by viral proteins that damage nerve cells directly by infecting cells of the brain and spinal cord. AIDS associated dementia occurs in six stages: normal, subclinical, mild, moderate, severe and end stage.

Report Overview @ https://www.transparencymarketresearch.com/aids-associated-dementia-market.html

Additionally, a severe form of AIDS associated dementia includes symptoms such as speech problems, muscle weakness, vision problems, and loss of bowel control.

Certain imaging diagnostic tests are used for the diagnosis of AIDS associated dementia: CT scan or MRI of the head and position emission tomography (PET). Other tests include spinal tap, Electroencephalography (EEG), and neuropsychological testing.

Based on the treatment, the AIDS associated dementia market can be segmented as follows:

Highly active antiretroviral therapy (HAART): Highly active antiretroviral therapy is used for the control of HIV infection and also protects people with HIV-positive from developing AIDS dementia complex

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3162

 

Drug medication: Certain drugs may improve the symptoms of AIDS associated dementia such as antidepressant medications are administered to treat depression and antipsychotic medications are used to treat severe aggression, hallucinations and delusions. Various novel drugs such as abacavir, efavirenz, d4T, and indinavir are used are used to lessen the extent of HIV infection in the cerebrospinal fluid of an individual.

Based on geography, the AIDS associated dementia market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. Out of these regions, North America dominates the market followed by Europe. The factors which are driving the growth of AIDS associated dementia market are increasing incidences of HIV infection amongst the population, and growing awareness regarding the loss of mental abilities caused due to AIDS associated dementia. According to Centers for Disease Control and Prevention (CDC), more than 1.1 million people in the United Sates are affected with HIV infection. Asia Pacific is one of the most promising markets for the growth of AIDS associated dementia market as the region is developing at a rapid pace. The advantageous factors which would accentuate the growth of the market in Asia Pacific are constantly increasing population density, and growing demand for more advanced treatment options especially non-surgical treatments. Furthermore, other factors such as major government support for various healthcare infrastructures, favorable reimbursement policies and easy market penetration would also fuel the growth of AIDS associated dementia market in the next few years.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=3162

Various clinical trials are in development for the AIDS associated dementia therapeutics. Some of the top players involved in the clinical trial with regards to AIDS associated dementia market are GlaxoSmithKline plc, Centaur Pharmaceuticals Pvt. Ltd., Bristol-Myers Squibb Company, Glaxo Wellcome GmbH & Co. KG, Glaxo Wellcome GmbH & Co. KG and many others.

Clostridium Botulinum Infections Market: Research Analysis by Basic Information, Manufacturing Base, Sales Area and Regions

Clostridium botulinum infections are caused by clostridium botulinum, a gram-positive, rod-shaped bacterium which produces an extremely lethal substance that is botulism neurotoxin. The spread of clostridium botulinum in human body leads to life-threatening neuroparalysis and can be deadly. It blocks the motor nerve terminal at the myoneural junction and causes flaccid paralysis. There are three different forms of botulism that are as follows:

Foodborne botulism: Foodborne botulism is caused by consuming food that is contaminated with botulinum toxin. For example, home-canned food or food kept in jars over extensive duration of time.

Infant/intestinal botulism: This is the most common form of botulism which affects infants aged less than a year. It results from absorption of botulinum toxin that immediately multiply in the gut and produce toxins

Report Overview @ https://www.transparencymarketresearch.com/clostridium-botulinum-infections-market.html

Wound botulism: When an open wound gets exposed to botulinum spores, the wound gets contaminated with botulinum spores, resulting in wound botulism

Various symptoms associated with clostridium botulinum infections are blurred vision, dilated pupils, nausea, difficulty in swallowing, extremely dry mouth, paralysis, constipation, and drooping eyelids.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3061

Based on treatment of botulism, the clostridium botulinum infections market can be segmented as follows:

Antitoxin Therapy: Antitoxins are antibodies that block the effects of botulism neurotoxin on the nervous system, i.e., nerves, brain and spinal cord. Another medication, known as botulism immunoglobulin is also used to treat infants.

Meticulous airway management: Meticulous airway management is used as respiratory problems are the most common threat to patients affected with clostridium botulinum infections

Mechanical breathing assistance: This treatment is a standard form of modern intensive care management in which the ventilator forces air into the patient’s lungs through a tube

Cathartics: As constipations is the first sign of botulism in infants, cathartics are given to accelerate defecation

Foley catheter: Foley catheter is used to treat bladder incontinence caused due to the infection. Special care must be taken to change the catheter regularly.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=3061

Based on geography, the clostridium botulinum infections market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. Out of these regions, North America holds a leading position in the market followed by Europe. The major factors which are driving the growth of clostridium botulinum infections market in these regions are increasing segment of the people who acquire clostridium botulinum infection, growing awareness about various toxic bacteria, and shift to sophisticated treatment tools. According to Centers for Disease Control and Prevention (CDC), in the U.S., approximately 145 cases of clostridium botulinum infection are reported each year, of which 15% are foodborne, 65% are infant botulism and 20% are wound botulism. Asia Pacific is considered to be the most promising market for the growth of clostridium botulinum infections market followed by Europe. The factors which would propel the growth of the market in Asia Pacific are presence of large population density in countries such as China, India and Brazil, where there is high prevalence of bacterial diseases, favorable reimbursement scenario for treatments and medications, tax benefits and huge government support to set up healthcare infrastructures such as hospitals and research clinics.

Some of the top players operating in clostridium botulinum infections market are DynPort Vaccine Company LLC, Emergent BioSolutions, Inc., XOMA Ltd., AlphaVax, Inc., Cangene Corporation, Morphotek, Inc., Molecular Targeting Technologies, Inc. and many others.

 

Ocular Pain Market Will Generate New Growth Opportunities By 2020

Ocular pain is also known as eye pain that occurs on the surface of the eye. Ocular pain is considered as a common medical condition that resolves on its own but, sometimes it creates emergency medical conditions. Possible causes for ocular pain includes corneal discomfort, pain in the sclera and discomfort in conjunctiva and pain in the iris. Moreover, few other etiology of ocular pain includes pain in extracellular muscle of the eye, burning sensation in nerves present in the eye and paining sensation on the eyelids. Sinusitis, migraines, traumatic events and glaucoma are considered as few of medical conditions that can cause ocular pain. possible signs and symptoms of ocular pain includes pain in the eye, partial loss of vision, light sensitivity, double vision, halos vision, severe headache, irregularly shaped pupil, bulging eye and blood inside the front of eye. Common test utilized for diagnosis of ocular pain includes slit-lamp exam, dilating drops test and tonometer test. Medications used for the treatment of ocular pain include antibacterial medications, antiviral medications and steroids.

Report Overview @ https://www.transparencymarketresearch.com/ocular-pain-market.html

Increasing unhygienic lifestyle among population is considered as a major market driving factor for the global ocular pain treatment market because bacterial and viral ocular infections are primarily observed among people with unhygienic lifestyle. Moreover, increasing awareness among people about eye related diseases would further accentuate the market growth in few developed nations of the world. Technological advancement in diagnostic test and increasing disposable income among population is also considered as a market driving factor of ocular pain treatment. However, lack of awareness and proper healthcare facilities present in few of the developing nations is considered as a factor that might restrict the global market demand of ocular pain treatment.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2718

North America and Europe was observed to be the largest ocular pain treatment market due to major market players are based in these regions. Moreover, technological advancement in diagnostic test and strong demand of diagnostic test would also account for the market growth in these regions. In addition, favorable initiative taken by the federal government also accounted for the ocular pain treatment market growth in North American and European regions. Increasing awareness among people about eye related diseases and its precautions is also considered as market deriving factor in North American and European regions. Similarly, Asia-Pacific is considered as an untapped market due to lack of proper diagnostic facilities in some Asian countries. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget).

Similarly, Asia-Pacific is considered as an emerging market due to growing market penetration in this region. Increasing disposable income among population is also accounted for the ocular pain treatment market growth in Asia-Pacific countries. Rest of the world (RoW) holds fourth position in the global ocular pain treatment market due to poor economic and health condition in most of the African countries. RoW market growth will be fuelled by extensive increase in healthcare infrastructure in Brazil and Mexico.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2718

Some of the major players in the Ocular Pain Market are Sylentis S.A., Bayer AG, InSite Vision Incorporated, Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., Bristol Meyer Squibb, Merck and Co. among others.

Cholangitis Market: Precise Analysis on Business Overview, Product Scope And Ongoing Market Development 2019

Cholangitis is referred as an infection of biliary tract that leads to significant mortality and morbidity. It is a bacterial infection that occurs when the bile duct that carries bile for liver to intestine and gallbladder is blocked by tumor or gallstone. Bile is a liquid generated by liver for food digestion.Abdominal pain, jaundice, fever and low blood pressure are some of the symptoms of cholangitis. Presence of pancreatic cancer slightly increases the risk of cholangitis. Diagnosis at an early stage and treatment of this disorder is very important. People above the age of 60 years are more prone to such disorders.

Report Overview @ https://www.transparencymarketresearch.com/cholangitis-market.html

Increasing geriatric population, changing lifestyle and increasing healthcare awareness are some of the important factors driving the growth of this market globally. Improvement in healthcare policies leads to increase in affordability of various healthcare treatments, this in turn, has increased the life expectancy of the population. Population above the age of 65 years usually suffer from various health disorders. Thus, increasing geriatric population globally augments the demand for cholangitis therapeutics market. Currently, many manufacturers are engaged in developing therapeutics for the treatment of cholangitis.

Geographically, North America is the leading region for the global cholangitis market owing to increasing geriatric population coupled with rising healthcare awareness. The market in Asia-Pacific region is expected to grow at a significant rate due to rise in disposable income and increasing healthcare awareness along with population aging.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2285

Some of the key players engaged in developing vasculitis therapeutics market are Gilead Sciences, RiemserArzneimittel AG, Bayer AG, Zambon Company S.p.A., Taiho Pharmaceutical Co., Ltd., Mayo Clinic and others.

Gastroesophageal Junction Carcinoma Treatments Market: Growth, Trends and Demands Research Report and Forecast 2019

Gastroesophageal (GE)junction carcinoma is a type of cancer thatdevelops between the esophagus and the tube that connects the stomach with the mouth. This type of cancer begins when carcinogens such as, alkylating agents or chemical particles enter in the esophagus or stomach. Alcohol consumption and tobacco smoking some of the major causes associated with gastroesophageal junction carcinoma.Prime symptoms of gastroesophageal junction carcinoma include weight loss, chest pain, fatigue, indigestion and dysphagia (difficulty to swallow food but comfortable with liquid). The symptoms of this condition are discovered on one to six month after the beginning of cancer. People with 60 to 70 years of ageand above are more prone to get this form of carcinoma.

Report Overview @ https://www.transparencymarketresearch.com/ge-junction-carcinoma-treatments.html

The global cancer treatment market is witnessing a rapid growth in Gastroesophageal Junction Carcinoma with the increase in the geriatric population worldwide and their high susceptibility to GE junction cancer. In June 2012, the American Geriatrics Society reported that about 30% of the American population were aged sixty five and above.High treatment cost associated with GE junction cancer is reported to be a major factor which will hinder the growth of this market.

Geographically, North America leads the global GE junction carcinoma market and is followed by Europe with the increase in awareness among the general population and technological developments in available treatments. However, high prevalence rate accounts Asia-Pacific (especially China) as an emerging growing market for GE junction carcinoma.

Some of the market players in this industry include, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, MedImmune, LLC, Millennium Pharmaceuticals, Inc., Amgen, Inc., Bristol-Myers Squibb Company and Merrimack Pharmaceuticals, Inc.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1887

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Pneumonia Drugs & Vaccines Market Emerging Technologies, Regional Trends, Competitive Landscape, Regional Analysis & Forecasts to 2019

Pneumonia is a common lung infection caused by a variety of microorganisms such as bacteria, virus, fungi and parasites. In pneumonia the air sacs of lungs that are known as alveoli are filled with fluid or pus causing inflammation. The common symptoms of pneumonia are cough with phlegm, sneezing, sore throat, chills, fever and trouble in breathing. Pneumonia is usually a mild disease but under certain situations can be lethal. Children, elderly people and those with recent viral infections, lung disease and heart disease are at higher risk of developing pneumonia compared to general population. Pneumonia is of different types depending on the way it has been acquired by people such community acquired pneumonia (CAP), hospital acquired pneumonia (HAP) and healthcare associated pneumonia as patient may also develop pneumonia during their visits to other healthcare setting such as nursing homes, dialysis centers and outpatient clinics. Others are aspiration pneumonia and atypical pneumonia. Pneumonia is one of the most common hospital acquired infection.

Report Overview @ https://www.transparencymarketresearch.com/pneumonia-drugs-vaccines-market.html

The global market for pneumonia is segmented broadly into treatment drugs and prevention vaccines market. Usually antibiotics used to treat pneumonia include cephalosporins, penicillin, tetracyclines, fluoroquinolones, amoxicillin, clavulanic acid and vancomycin. Earlier, penicillin was widely used to treat pneumonia caused by bacteria pnemococcal pneumonia but due to wide spread use of broad spectrum antibiotics has resulted into significant drug resistance. Penicillin is still used but only after confirming the sensitivity of the bacteria towards this antibiotic. Pneumococcal conjugate vaccine such as PCV13 and pneumococcal polysaccharide vaccines such as PPV23 and Pneumovax are used to prevent pneumococcal diseases. The major players operating in this market are Sanofi, Eli Lilly, AstraZeneca, Merck & Co. Novartis, GlaxoSmithCline, Pfizer and Baxter International Inc.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1735

The market for pneumonia drugs and vaccines is expected to grow under the impact of drivers such as increasing aging population as aging population are more susceptible to developing pneumonia and increasing prevalence of pneumonia among children. According to WHO, every year approximately 1.2 million children under the age of five years die because of pneumonia. WHO also reports only 30% of children suffering from pneumonia get required antibiotics for the treatment of pneumonia. This disease is most prevalent in South Asia and African countries.

Incretion Drugs Market Will Generate New Growth Opportunities By 2019

Incretion is a process of internal secretion of hormone through endocrine glands. These hormones control the major internal body functions such as digestive activities and movement. Sometimes these hormones are not secreted in an appropriate amount to control internal body functions. When such situation arises, a patient is advised for intake of incretion drugs. These incretion drugs stimulate secretion of various endocrine hormones as per the body requirement.

Report Overview @ https://www.transparencymarketresearch.com/incretion-drugs-market.html

Prescription of an incretion drug varies as per the disease condition. A patient may suffer from endocrinal disorders such as diabetes; thyroid and infertility for which incretion drugs could be prescribed. In addition, these drugs could also be prescribed when pituitary and adrenal glands fail to secrete hormones in appropriate amount. Various incretion drugs include Orinase (tolbutamide), Amaryl (gimepiride), Glucotrol XL (glipizide), Glucotrol (glipizide), Micronase (glyburide), DiaBeta (glyburide), Glynase PresTab (glyburide, micronized), Prandin (repaglinide) and Starlix (nateglinide). Other incretion drugs are Januvia, Onglyza, Tradjenta, Glucovance, Metaglip, ActoPlus Met, Avandamet, Duetact, Avandryl, PrandiMet, Janumet, PrandiMet, ActoPlus Met XR and Kombiglyze XR.

Rise in geriatric population globally would augment the growth of these drugs market. In addition, rise in complexities of pregnancy such as overt diabetes, infertility, hormonal imbalance would also boost the growth of this market. Moreover, rise in obese population worldwide is anticipated to further trigger the demand for these medicines. According to the Department of Health Statistics and Information Systems at WHO, around 12% of the total world population suffers every year from obesity. These incretion drugs have proven to be beneficial for treatment of obesity.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1556

Some of the major players in this market are Abbott Laboratories, Bayer Healthcare, Novartis, Eli Lilly, and Bristol-Myers Squibb amongst other significant players.

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Phosphate Binding Agents Market: Emerging Trends, Business Growth Opportunities, Major Driving Factors

Cardiovascular diseases and diabetes lead to common complications such as nephrology and urology disorders. Unhealthy food habits and drugs are known to cause nephrological and urological diseases. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 26 million people have chronic kidney diseases in the U.S. The statistics show that about 87,000 patients die due to kidney failure every year. Commonly used drug classes for treating nephrological and urological disorders include diuretics, anti-hypertensive drugs, phosphate binders, and anti-cholinergic and 5-alpha-reductase inhibitors. Phosphate binders are drugs which are used to lower the absorption of phosphate in patients suffering from chronic renal failure due to their inability to remove phosphorus naturally. Excess deposition of phosphorus in the body, especially in a kidney failure patient, results in the depletion of calcium from bones and ultimately leads to diseases such as hyperphosphatemia and renal osteodystrophy or renal bone. Phosphate binders work by binding phosphate in the gastrointestinal tract, ultimately making it unavailable to the body for absorption. In June 2014, Keryx Biopharmaceuticals, Inc. received patent for Zerenex, a ferric citrate based phosphate binder, which will expire in 2024. The company has filed new drug application (NDA) for Zerenex and is currently under review by the U.S. FDA. Sanofi lost patent for Renvela (sevelamer) in 2014; the drug generated a total revenue of US$ 750 Mn in 2013. Other key drugs in the market include Alucap (aluminum hydroxide) by Meda Pharma, Calcichew (calcium carbonate), Renagel (sevelamer) by Genzyme Corporation, and Fosrenol (lanthanum carbonate) by Shire US, Inc.

Report Overview @ https://www.transparencymarketresearch.com/phosphate-binding-agents-market.html

The rising prevalence of chronic kidney diseases is a major factor driving the growth of the global phosphate binding agents market. For instance, over 20 million people in America are affected by chronic kidney diseases; the incidence rate of these diseases is rapidly growing among people above the age of 65 years. The FDA has approved the use of these phosphate binding agents in hyperphosphatemia secondary to chronic kidney diseases. In addition, rising awareness about the complications caused due to chronic kidney diseases and the treatment options is fueling the growth of the global market. However, phosphate binding agents have certain gastrointestinal reactions such as diarrhea, nausea, vomiting, and abdominal pain, leading to their discontinuation. This factor is restraining the growth of the market for phosphate binding agents.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35699

The global phosphate binding agents market has been segmented based on type, application, distribution channel, and region. In terms of type, the market is segmented as calcium-based phosphorus binders; aluminum-free, calcium-free phosphorus binders; aluminum-based phosphorus binders; and magnesium-based phosphorus binders. The calcium-based phosphorus binders segment primarily includes calcium carbonate and calcium acetate. These calcium-based phosphorous binders have largely replaced aluminum-based phosphorous binders, and these binders also serve as calcium supplements. In terms of application, the market is segmented as hyperphosphatemia, hyperphosphatemia of renal failure, osteodystrophy, and anemia. In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online retailers, and private clinics.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=35699

Geographically, the global phosphate binding agents market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for the largest market share owing to high research and development, favorable reimbursement policies, and availability of advanced health care infrastructure. The implementation of the Affordable Care Act has significantly posed limitations to hospitals as well as pharmaceutical companies with respect to costing of new drugs. Europe is the second largest market for phosphate binding agents due to presence of high quality scientific companies and research organizations. However, lack of proper reimbursement policies and regulatory framework pertaining to new drug development could restraint the growth of the Europe market during the forecast period.

Key players operating in the global market include Shire US, Inc., Meda Pharma, and Genzyme Corporation.

Hemorrhagic Septicemia Vaccines Market Size & Share - Industry Trend and Forecast 2017 - 2025

Hemorrhagic septicemia (HS), is an economically important disease of buffaloes and other cattle, in warm regions of Asia, primarily in Southeast Asia, where the population of aquatic buffaloes is high. It is caused by a microorganism Pasteurella multocida. Vaccination for this disease is practiced widely in different geographies of the world. Generally, aluminium hydroxide gel vaccines, alum precipitated vaccines and/or bacterins are administered two times in a year for disease prevention. This is done twice a year due to the fact that these vaccines offer an immunity for four to six months. Several countries use OAV or oil adjuvant vaccine, which gives longer duration and high degree of immunity, i.e., upto a year. Experimentally, a multiple emulsion and/or a double emulsion vaccine comprises a thin viscosity have also been developed by scientists which are given with OAV. At present, from a strain of fallow deer, a live vaccine has been developed in Myanmar. This live vaccine offers an immunity for more than a year, but it has its own limitations. The current review gives information about the vaccine for hemorrhagic septicemia, which has been developed using whole bacteria or components of bacteria.

Report Overview @ https://www.transparencymarketresearch.com/hemorrhagic-septicemia-vaccines-market.html

Traditional hemorrhagic septicemia is defined by the Organization for Animal Health (OIE) as it is affected by Pasteurella multocida serotypes E:2 and B:2 (Heddleston and Carter classification system) serotypes. Serotype B:2 has been identified in maximum parts of the world, where the disease is endemic, while serotype E:2 has been identified in Africa only. Septicemic pasteurellosis, which is clinically related to hemorrhagic septicemia can be spread by a wide range of other P. multocida serotypes and has been reported worldwide. Normally killed or inactivated vaccines are used for the prevention of hemorrhagic septicemia. Other vaccines such as oil adjuvant vaccines, aluminum hydroxide gel vaccines, alum-precipitated vaccines and bacterins are also used for prevention of hemorrhagic septicemia. In animals of more than three years of age, an early two dosages, one to three month separately, is suggested, followed by booster vaccinations once or twice yearly.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33884

The oil adjuvant vaccine offers protection for 9 to 12 month and is given on a yearly basis. However, it is not popular among users owing to the difficulty in its administration and viscosity. Oil-based vaccines amalgamate with saponin or tween 80 and are have also been used to increase the immune protection and simplify administration. The generally used aluminum hydroxide gel alum-precipitated vaccines have shorter duration of immunity, and twice-yearly booster vaccinations are suggested. Modified live or attenuated vaccines have been used with little success. A live virulent vaccine developed from a P. multocida serotype B:3 of fallow deer source appears active and is suggested for usage by the Food and Agricultural Organization of the United Nations (FAO) in Southeast Asia. Several subunit and altered live vaccines prepared from any recombinant or purified bacterial constituents have also been examined experimentally. There are several factors boosting the hemorrhagic septicemia vaccines market, which include technological innovations, increase in awareness about animal health, and rise in funding from government organizations and associations. Additionally, increase in the demand for milk and animal protein and rise in expenditure on health care of companion animals is driving the hemorrhagic septicemia vaccines market.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=33884

The global hemorrhagic septicemia vaccines market has been segmented based on type of product, application, end-user, and geography. In terms of type of product, the hemorrhagic septicemia vaccines market has been bifurcated into oil adjuvant vaccines and aluminum hydroxide-adjuvant vaccines. Based on application, the market has been categorized into cattle, buffaloes. In terms of end-user, the market has been classified into veterinary hospitals, veterinary clinics, and animal care centers. Based on geography, the hemorrhagic septicemia vaccines market has been divided into North America, Europe, Asia Pacific, and Rest of the World (RoW).
Major players operating in the global hemorrhagic septicemia vaccines market are Ceva, OVEJERO, Institute of Veterinary Preventive Medicine, Bio-Labs, Brilliant Bio Pharma Private Limited, C.A. LABORATORIOS ASOCIADOS, VECOL, FATRO, Indian Immunologicals Limited, Institute of Animal Health and Veterinary Biologicals, Intevac Pvt. Ltd., etc.

Pediatric Cannulae Market: Growth Analysis, Trends and Scope till 2025

Cardiac surgery has experienced a tremendous growth in technological advancement, and the coronary bypass grafting has become routinely safe worldwide. Advancements in valve repair and replacement have improved the outcomes for patients each year who are afflicted with valvular heart diseases. Congenital heart defects can be repaired in infants, even those weighing less than 2 kg with a positive outcome. The cardiopulmonary bypass surgery is used to repair cardiac defects, and cannulae play a vital role during this process as these tubes provide bloodless and motionless environment to cardiothoracic surgeons to repair the defects.

Report Overview @ https://www.transparencymarketresearch.com/pediatric-cannulae-market.html

The growth of the global pediatric cannulae market is driven by the rise in incidence of congenital heart defects among infants, advancement in pediatric surgical procedures, and innovative product development by key players. Furthermore, rising health care expenditure, advancement in health care facilities in developing countries, and government initiatives to create awareness about congenital heart defects are the major factors driving the market growth of the global pediatric cannulae market. However, rising cost of equipment and lack of skilled cardiothoracic surgeons and physicians to perform surgeries are the factors which are restricting the growth of the global market. On the other hand, penetration of regional or local players with low cost devices is likely to boost the growth of the market in emerging economies.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34154

The global pediatric cannulae market has been segmented by product, material type, end-user, and region. Based on product, the global pediatric cannulae market is segmented into extracorporeal and cardioplegia products. The extracorporeal products segment is further segmented into arterial cannulae, femoral cannulae, and venous cannulae. Arterial cannulae are used to return oxygenated blood to the patient during the cardiopulmonary bypass surgery. The femoral cannulae are used for placement in femoral vein and are ideally suited for percutaneous and direct insertion. Venous cannulae are designed to provide venous drainage. The cardioplegic products segment is divided into antegrade cannulae and retrograde cannulae. The antegrade cardioplegia cannula allows the supply of solutions via coronary arteries, and in retrograde cardioplegia cannula, solutions are supplied through coronary veins. The retrograde cannulae sub-segment is further divided into manually inflating balloon and self-inflating balloon.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=34154

In terms of material type, the market is segmented into biocompatible material, polyurethane, polyvinyl chloride (PVC), silicone, and others. In terms of end-user, the market is divided into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the pediatric cannulae market owing to rising patient preference towards established hospitals for cardiac surgeries, growing number of patients, and growing adoption of new products and techniques by hospitals in the treatment of cardiac disorders.

Based on region, the global pediatric cannulae market is distributed over five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global pediatric cannulae market in terms of revenue during the forecast period, followed by Europe. This is attributed to factors such as advancements in the treatment of congenital heart diseases, which has enabled healthcare providers to efficiently treat neonates, pediatric and infants suffering from congenital heart defects. However, Asia Pacific is projected to expand at a high CAGR during the forecast period due to growing prevalence rate of cardiovascular diseases among children, increasing adoption of minimally invasive techniques, and rising government funding and initiatives in creating awareness about pediatric congenital heart diseases.

Key players operating in the global pediatric cannulae market include MAQUET Holding B.V. & Co. KG, Becton Dickinson, Medtronic Inc., Edwards Lifesciences Corporation, Sorin Group, Braile Biomédica, ANDOCOR n.v., DTR Medical, Medline Industries, Inc., Mortech Industries, and Eurosets.

Optic Neuritis Treatment Market Future Opportunities 2025

Demyelinating inflammation of optic nerve is referred as optic neuritis. It is also commonly termed as optic papillitis and retro tubular neuritis. In most cases, optic neuritis is found to be associated with multiple sclerosis and can lead to partial or complete vision loss. Other diseases likely to be diagnosed along with optic neuritis in early stages include hyperkalemia and diabetes mellitus. Major symptoms associated with optic neuritis are partial or complete vision loss, blurred vision, pain in eyes, etc. In several cases, primary symptoms of optic neuritis include photophobia, reduced night vision, and eye redness. Adult optic neuritis and pediatric optic neuritis are two types based on age group of patients diagnosed with optic neuritis. The optic nerve consists of axons arising from retina and transmitting visual information to visual nuclei. Inflammation of this optic nerve causes improper functioning and can lead to vision loss because of destruction of myelin sheath attached to optic nerve. 40% to 50% patients with multiple sclerosis (MS) develop optic neuritis and around 30% optic neuritis patients show symptoms of multiple sclerosis. A recent article published in the Journal of Neurology stated that the annual incidence of optic neuritis in the U.S. is found to be around 5/1,000,000, with estimated prevalence 115/1,000,000.

Report Overview @ https://www.transparencymarketresearch.com/optic-neuritis-treatment-market.html

Growing awareness about early detection of optic neuritis associated with multiple sclerosis and availability of affordable treatment options are expected to drive the global optic neuritis treatment market during the forecast period. Increase in geriatric population, rise in multiple sclerosis patient pool, growing awareness and affordable prices are the major factors propelling the market. Side effects of optic neuritis treatment drugs and growth of the generic drugs market are likely to restrain the global optic neuritis treatment market during the forecast period. Availability of reimbursement and well-established health care infrastructure are other factors expected to augment the market during the forecast period.

The global optic neuritis treatment market can be segmented based on type of therapy, distribution channel, and region. In terms of type of therapy, the market can be categorized into steroidal therapy, supplementary therapy, and immunomodulators therapy. Steroidal therapy includes cortecostreoidal drugs, which have proven efficacy for decades. Steroidal therapy is projected to hold major market share due to proven efficacy and easy availability. Supplementary therapy includes vitamin supplementation therapy with vitamin B12 and is considered to be adjacent therapy in the treatment of optic neuritis. Immunomodulators therapy involves disease modifying agents such as interferons beta1a and beta1b which are beneficial in optic neuritis and multiple sclerosis.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34064

Based on distribution channel, the global optic neuritis treatment market can be divided into hospitals, ophthalmic clinics, and ambulatory surgical centers. The hospitals segment captured a major market share and is likely to sustain its leadership position during the forecast period. A large population prefers visiting hospitals first rather than ophthalmic clinics for treatment as the cost of therapy at hospitals is lower. Ambulatory surgical centers is the less preferred option for the treatment of optic neuritis.

Geographically, the global optic neuritis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America projected to be the largest market during the forecast period. The region is anticipated to continue to dominate the market during the forecast period due to increase in the geriatric population, growing awareness among the population regarding MS and optical neuritis, and well-established health care infrastructure. Europe is expected to be the next dominant region during the forecast period due to increase in volume sales of steroidal therapeutics especially corticosteroids and upcoming new launches of combined medication products. The market in Asia Pacific is likely to expand at a high CAGR during the forecast period. The market in Latin America and Middle East & Africa is projected to expand at a sluggish CAGR during the forecast period. Increased focus by federal governments on enhancing health care facilities and rising awareness among the population are the factors contributing to the growth of the market in these regions.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=34064

A small number of players operate in the global optic neuritis treatment market; however, several companies are interested in investing in the market due to increase in demand for the therapy. Major players operating in the global optic neuritis treatment market are Biogen, Mallinckrodt Pharmaceuticals Inc., Pfizer, Inc., Novartis AG., and Teijin Pharmaceutical Limited, among others.

Trichomoniasis Drugs Market Emerging Technologies, Regional Trends, Competitive Landscape, Regional Analysis & Forecasts to 2025

Trichomoniasis is a sexually transmitted disease (STD) which is caused by the flagellated protozoan parasite passed from one person to another during sex; the parasite usually transmits from a vagina to a penis or from penis to a vagina, and some time, from a vagina to another vagina. Men and women are suffering from trichomoniasis globally. The commonly infected part of the body in women is the lower genital tract (vulva, cervix, vagina, or urethra), while that in men is the inside of the penis (urethra). Trichomoniasis can be asymptomatic or can cause vaginitis, urethritis, or occasionally epididymitis, cystitis, or prostatitis. Burning after urination or ejaculation, itching, redness or soreness of genitals, itching or irritation inside the penis, discomfort while urinating in women, discharge from the penis, dyspareunia, yellow-green, frothy vaginal discharge with soreness of the vulva and perineum, dysuria, urethritis, and purulent area are some of the common symptoms of trichomoniasis. Epididymitis and prostatitis are the major complications of trichomoniasis.

Report Overview @ https://www.transparencymarketresearch.com/trichomoniasis-drugs-market.html

Nucleic acid amplification tests (NAAT), direct fluorescent tests, direct microscopic examination of vaginal secretions, and immunochromographic are the common tests recommended by health care specialists for the diagnosis of trichomoniasis. Trichomoniasis is suspected in men with urethritis, in women with vaginitis, or in their sexual partners. According to a report published by the WHO, trichomoniasis cases are higher in number than chlamydia or gonorrhea cases every year. Trichomoniasis can be treated with metronidazole or tinidazole. Tinidazole is an anti-parasitic drug, while metronidazole is an antibiotic and antiprotozoal medication used for the treatment of trichomoniasis. Metronidazole is available in the market under brand name, Flagyl.

The global trichomoniasis drugs market is expanding significantly due to increase in the incidences of trichomoniasis. Rise in cases of unprotected sex has contributed to the spread of the disease. Low voluntary screening rate for the disease is a major restraint of the market. Awareness about trichomoniasis diagnostic tests is poor in the countries in Africa. Therefore, companies are facing challenges with regard to market penetration in the region. Moreover, several low and middle-income countries depend on government grants for the provision of rapid diagnostic tests in the event of an epidemic. Thus, direct reach to customers is limited in these countries. These factors hamper the growth of the trichomoniasis drugs market in the region.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34040

The global trichomoniasis drugs market can be segmented based on drug type, distribution channel, and region. In terms of drug type, the market can be categorized into metronidazole and tinidazole. In terms of distribution channel, the global trichomoniasis drugs market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. Based on revenue, the hospital pharmacies segment constituted a significant share of the trichomoniasis drugs market in 2016.

In terms of region, the global trichomoniasis drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for trichomoniasis drugs. In terms of revenue, the U.S. accounts for the dominant share of the trichomoniasis drugs market in North America. The market in Europe is expanding rapidly due to an increase in the number of patients, especially in the U.K. and Germany. The markets in Asia Pacific and Latin America are projected to expand significantly in the near future. Developing economies such as China and Japan are anticipated to contribute to the growth of the market in the region between 2017 and 2025 due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increase in awareness among people.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=34040

Key players operating in the global trichomoniasis drugs market are Pfizer, Inc., Lupin Ltd., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Valeant Pharmaceuticals International, Inc., Mission Pharma, Unique Pharmaceutical Laboratories Ltd., and Edenbridge Pharmaceuticals among others.

ACTH and GH Function Tests Market: Analysis and Research Report by Experts 2025

Adenocorticotropic hormone (ACTH) is a hormone produced and secreted by the anterior pituitary gland. It is also called corticotropin or serum ACTH. The function of the ACTH is to regulate the level of steroid hormone cortisol, which is regulated by the adrenal gland. Growth hormone (GH) is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration. Growth hormone is also known as somatotropin or human growth hormone (HGH). Growth hormone is produced by the pituitary gland. It is a stress hormone that increases the levels of glucose and free fatty acids. ACTH is associated with diseases such as pituitary tumor and adrenal malfunction. GH is associated with acromegaly and gigantism. Hence, ACTH and GH testing is an important factor to control and cure diseases.

Report Overview @ https://www.transparencymarketresearch.com/acth-gh-function-tests-market.html

Rise in unhealthy lifestyle, growing stress levels, and unhealthy food habits that result in obesity that disturbs the levels of hormone are important factors likely to propel the global ACTH and GH function tests market during the forecast period. According to American Association of Neurological Surgeons, 10–15 persons per million people are affected every year with Cushing’s syndrome. Rise in the prevalence of Cushing syndrome and Addison disease is a major factor anticipated to fuel the global ACTH function tests market throughout the forecast period. Increasing prevalence of growth hormone deficiency (GHD) in children and rising prevalence of gigantism and child obesity are key factors likely to augment the global ACTH and GH function tests market during the forecast period. Additionally, rise in the prevalence of chronic diseases such as pituitary disorders, disturbing thyroid levels, high blood pressure, and increase in the prevalence of kidney disorders and hypogonadism are factors that are likely to drive the market from 2017 to 2025. According to the WHO, the number of diabetes patients worldwide would increase to 366 million by 2030, promoting rapid growth of the global ACTH and GH function tests market during the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33569

Based on technology, the global ACTH and GH function tests market has been divided into serology & immunoassays, molecular techniques, mass spectrometry, and others. The mass spectrometry segment is expected to register a high growth rate throughout the forecast period, due to advantages of mass spectrometry over traditional serology methods. Based on sample type, the market has been divided into blood, urine, and others. Based on end-user, the global ACTH and GH function tests market has been segregated into hospitals, diagnostic laboratories, ambulatory surgical centers, and other home care settings. The home care setting segment is anticipated to witness high between 2017 and 2025, due to cost-effective and user-friendly ACTH and GH function test kits offered under this segment.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=33569

Based on geography, the ACTH and GH function tests market has been segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global ACTH and GH function tests market, both in terms of value and volume, followed by Europe. Developed hospitals, improved technology, increase in awareness about health care, and proper reimbursement are factors attributable to growth of the market in North America. The Asia Pacific market is expected to register a high growth rate during the forecast period, owing to factors such as developing health care network, improved hospital infrastructure, and rising awareness among people in the region.

Some of the key players operating in the global ACTH and GH function tests market are GenWay Biotech, Inc., LifeSpan BioSciences, Inc., Abcam plc, F. Hoffmann-La Roche Ltd, Abbott laboratories, and Laboratory Corporation of America. In order to maintain a significant position in the global market, major players are involved in launching highly efficient products and initiate collaborations and mergers. For example, Laboratory Corporation of America offers solutions for every hormonal disease. The company also offers Liquid Chromatography Mass Spectrometry (LC-MS), which requires a minimal amount of sample.